Status:
RECRUITING
ASL in Brain Metastasis MRI Following Gamma Knife Treatment
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Brain Metastases
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Arterial spin labeling (ASL) is a non-invasive MRI technique that could help the radiologists to distinguish brain metastasis progression versus radionecrosis following gamma-knife treatment. The pri...
Detailed Description
The metastasis progression versus radionecrosis following GK treatment can sometimes be difficult to distinguish. 60 patients will be included in this prospective, monocentric study. 3 MRI (baseline, ...
Eligibility Criteria
Inclusion
- Brain metastasis from histologically proven tumor
- GK treatment within 4 month prior to the inclusion
- Lesions suspected of progression/ radionecrosis :
- i.e.≥ 25% of the size progression
- Lesion size: gadolinium enhanced part of the tumour ≥1 cm
Exclusion
- Pregnancy
- Medical history of primitive brain tumour
- MRI incompatibility/ medical history of contrast agent allergy
- Claustrophobia
- Patient unable to consent
- Epilepsia/recent stroke
- Patients participating in other studies
- Patients without health care insurance
Key Trial Info
Start Date :
January 24 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 24 2028
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04833335
Start Date
January 24 2023
End Date
September 24 2028
Last Update
August 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de neuroradiologie, hôpital Pitié Salpêtrière
Paris, France, 75013